NASDAQ:ATNF 180 Life Sciences (ATNF) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free ATNF Stock Alerts $1.77 -0.05 (-2.75%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.68▼$1.8250-Day Range$1.48▼$4.1552-Week Range$1.33▼$27.93Volume15,531 shsAverage Volume106,529 shsMarket Capitalization$1.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get 180 Life Sciences alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About 180 Life Sciences Stock (NASDAQ:ATNF)180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Read More ATNF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATNF Stock News HeadlinesMarch 14, 2024 | finanznachrichten.de180 Life Sciences Corp.: 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price RequirementMarch 14, 2024 | finance.yahoo.com180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price RequirementApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 14, 2024 | globenewswire.com180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price RequirementFebruary 26, 2024 | markets.businessinsider.com180 Life Sciences Announces 1-For 19 Reverse Stock Split - Quick FactsFebruary 26, 2024 | globenewswire.com180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance PlanFebruary 17, 2024 | thestreet.com180 Life Sciences Corp.December 20, 2023 | benzinga.com180 Life Sciences Stock (NASDAQ:ATNF), Quotes and News SummaryApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.December 4, 2023 | marketwatch.com180 Life Sciences Hires Financial Adviser to Help Explore Strategic AlternativesDecember 4, 2023 | finance.yahoo.com180 Life Sciences Engages Financial Advisor to Explore Strategic AlternativesNovember 28, 2023 | finanznachrichten.de180 Life Sciences Corp.: 180 Life Sciences Announces Review of Strategic AlternativesNovember 28, 2023 | finance.yahoo.com180 Life Sciences Announces Review of Strategic AlternativesOctober 7, 2023 | nasdaq.com180 Life Sciences Corp. Common Stock (ATNF)September 15, 2023 | benzinga.comInnovative Biotech Company Announces Agreement To Perform CBD Pill Clinical StudyAugust 14, 2023 | finance.yahoo.com180 Life Sciences Corp. Announces Closing of $3 Million Public OfferingAugust 7, 2023 | benzinga.com180 Life Sciences Teams Up With Hadassah Hospital To Test A New Formulation Of CBD For Enhanced Oral UptakeAugust 7, 2023 | finance.yahoo.com180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral UptakeAugust 3, 2023 | finance.yahoo.com180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDAJuly 31, 2023 | benzinga.com180 Life Sciences Files A Provisional Patent For CBD-Based Appetite SuppressantJuly 31, 2023 | finance.yahoo.com180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress AppetiteApril 10, 2023 | finance.yahoo.com180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private PlacementApril 5, 2023 | finance.yahoo.com180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private PlacementApril 5, 2023 | investorplace.comWhy Is 180 Life Sciences (ATNF) Stock Up 30% Today?February 28, 2023 | finance.yahoo.com180 Life Sciences Announces Presentation at the Gordon ConferenceFebruary 27, 2023 | finance.yahoo.com180 Life Sciences Announces Presentation at the Gordon ConferenceFebruary 23, 2023 | finance.yahoo.com180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and ApplicationSee More Headlines Receive ATNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATNF CUSIPN/A CIK1690080 Webwww.kblmerger.com Phone(650) 507-0669FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-320.26% Return on Assets-112.07% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.24) per share Price / Book-7.35Miscellaneous Outstanding Shares850,000Free Float818,000Market Cap$1.50 million OptionableNo Data Beta0.44 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Lawrence Steinman BA (Age 76)M.D., Ph.D., Co-Founder & Executive Chairman Comp: $168.75kDr. James N. Woody M.D. (Age 82)Ph.D., CEO & Director Comp: $617.77kMr. Ozan Pamir C.F.A. (Age 32)CFO & Secretary Comp: $410.24kDr. Jonathan B. Rothbard Ph.D. (Age 71)Chief Scientific Officer Comp: $260.34kProf. Jagdeep NanchahalCo-Founder & Chairman of Clinical Advisory BoardMr. Jason AssadDirector of IRMore ExecutivesKey CompetitorsNeuBase TherapeuticsNASDAQ:NBSEInMed PharmaceuticalsNASDAQ:INMHistogenNASDAQ:HSTOPanbela TherapeuticsNASDAQ:PBLAGRI BioNASDAQ:GRIView All CompetitorsInsidersJr. Donald A McgovernBought 526 shares on 5/31/2023Total: $11,493.10 ($21.85/share)James N WoodyBought 2,105 shares on 5/18/2023Total: $41,194.85 ($19.57/share)Pamela G MarroneBought 372 shares on 5/18/2023Total: $7,492.08 ($20.14/share)Ozan PamirBought 271 shares on 5/18/2023Total: $5,200.49 ($19.19/share)View All Insider Transactions ATNF Stock Analysis - Frequently Asked Questions How have ATNF shares performed in 2024? 180 Life Sciences' stock was trading at $4.0565 at the start of the year. Since then, ATNF shares have decreased by 56.5% and is now trading at $1.7650. View the best growth stocks for 2024 here. Are investors shorting 180 Life Sciences? 180 Life Sciences saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 17,100 shares, a decline of 59.7% from the March 31st total of 42,400 shares. Based on an average trading volume of 103,100 shares, the short-interest ratio is presently 0.2 days. Currently, 3.3% of the company's shares are short sold. View 180 Life Sciences' Short Interest. When is 180 Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ATNF earnings forecast. When did 180 Life Sciences' stock split? Shares of 180 Life Sciences reverse split on the morning of Wednesday, February 28th 2024. The 1-19 reverse split was announced on Wednesday, February 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of 180 Life Sciences? Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATNF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
